|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NF-кB has been linked to doxorubicin resistance in breast cancer patients.
|
24344116 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Docetaxel, frequently used for the treatment of breast cancer, is mainly metabolized via hepatic cytochrome P450 (CYP) 3A in humans and is also a substrate of P-glycoprotein (P-gp).
|
29679509 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, RNA samples from 64 paired patient tumors (before and after chemotherapy) highly and significantly overexpressed Pygo2 and/or MDR1 after treatment, thus underlining a pivotal role for the Pygo2-mediated Wnt/β-catenin pathway in the clinical chemoresistance of breast cancer.
|
26876203 |
2016 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The multidrug resistance phenotype of human breast carcinoma MCF-7/AdrVp cells is characterized by overexpression of a 95-kilodalton membrane glycoprotein (p95), accompanied by a marked reduction in intracellular anthracycline accumulation, without overexpression of P-glycoprotein or the multidrug resistance protein.
|
8674037 |
1996 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Peripheral blood mononuclear cells from 127 Japanese women with breast cancer who received weekly adjuvant paclitaxel were used to genotypes SLCO1B3 rs4149117" genes_norm="28234">T334G (rs4149117), CYP2C8 rs10509681" genes_norm="1558">A1196G (rs10509681), ABCB1 C1236T (rs1128503), ABCB1 G2677T/A (rs2032582), and ABCB1 C3435T (rs1045642).
|
28447211 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The compounds also interacted with either multiresistant proteins (MRPs), P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP) and increased significantly (3-4-fold) the cellular accumulation of anti-cancer agent vinblastine (VBL).
|
30149128 |
2018 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to study the association between genetic polymorphism of MDR1 at three sites (C3435T, G2677A/T, and C1236T) and their haplotype and the risk of breast cancer in Jordanian females.
|
26838221 |
2016 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nonetheless, the precise molecular mechanisms responsible for high or low level P-gp expression in breast cancer cells have not been established.
|
15034303 |
2004 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nuclear expression of the Y-box-binding protein (YB-1) has been reported to correlate with the expression of P-glycoprotein in breast cancer and osteosarcoma.
|
12533839 |
2003 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Together, these data reveal a protective function for peroxiredoxins in MCF-7 cell survival, and suggest that Prdx overexpression in breast cancer may play a role in doxorubicin-resistance in these, and possibly other, breast cancer cells.
|
24789097 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
STAT3 can be constitutively activated in breast cancer, maintains the tumor initiating cell (TIC) population, and upregulates multidrug resistance protein 1 (MDR1).
|
29262529 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Appearance and detection of multiple copies of the mdr-1 gene in clinical samples of mammary carcinoma.
|
1612774 |
1992 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy.
|
9285118 |
1997 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines.
|
24492650 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression, DNA binding, and transactivating activity of activator protein 1 (AP-1) was examined in a series of multidrug resistant (MDR) MCF-7 human breast cancer cells that have increasing levels of MDR1 gene expression.
|
10369069 |
1999 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RNAseq analysis confirmed the expression of key BBB-related genes in the hiPSC-derived endothelial cells in comparison with primary human brain microvascular endothelial cells, including P-glycoprotein (Pgp) and breast cancer resistant protein (BCRP).
|
31079318 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In MCF-7 drug-sensitive breast cancer cells, asGCS ODN-7 only increased doxorubicin sensitivity by 3-fold, and it did not influence doxorubicin cytotoxicity in normal human mammary epithelial cells. asGCS ODN-7 was shown to be more efficient in reversing drug resistance than either the GCS chemical inhibitor d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or the P-glycoprotein blocking agents verapamil and cyclosporin A.
|
14967819 |
2004 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This article discusses the evidence that P-gp expression may be implicated in the development of clinical drug resistance in patients with breast cancer.
|
1682166 |
1991 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The study was focused on the inhibition of MDR by blocking the ADR1 gene expression and through the inhibition of the pump-function of mdr-p-glycoprotein, in human breast cancer cell lines expressing mrp and prostate cancer cell line (PC-3).
|
15161039 |
2004 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein.
|
21562851 |
2012 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.
|
20179710 |
2010 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MCF-7/AdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent reduction in the intracellular accumulation of anthracycline anticancer drugs in the absence of overexpression of known multidrug resistance transporters such as P glycoprotein or the multidrug resistance protein.
|
9861027 |
1998 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The level of glutathione (GSH), activities of glutathione-S-transferase (GST), glutathione-peroxidase (GPx), 06-alkylguanine-DNA-alkyltransferase (ATase), and P-glycoprotein (PGP) were measured in tumor and adjacent tumor free tissue samples from 89 consecutive, untreated females with breast cancer and correlated with clinical and prognostic factors.
|
9209662 |
1997 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Transduction of the breast cancer cell line 4T1 with adenoviral vectors encoding the HA117 gene and the green fluorescence protein gene (GFP) (Ad-GFP-HA117), the MDR1 and GFP (Ad-GFP-MDR1) or GFP (Ad-GFP) was respectively carried out.
|
20642825 |
2010 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our results reveal the potential regulatory mechanism of FTH1P3 on breast cancer paclitaxel resistance through miR-206/ABCB1, providing a novel insight for the breast cancer chemoresistance.
|
29971911 |
2018 |